KRAS and familial pancreatic carcinoma: In cellular assays, a dimeric versionof our most potent agent, we termed targefrin, induces receptor degradationat nanomolar concentrations, similar to the effect of ephrinA1-Fc,as assessed by western blot analysis in pancreatic cancer cell linesBxPC3, PANC-1, and MIA PaCa2, representing KRAS wild-type (BxPC3)and KRAS-mutant (PANC-1 and MIA PaCa2) tumors.